Cargando…

HPV-Specific Systemic Antibody Responses and Memory B Cells are Independently Maintained up to 6 Years and in a Vaccine-Specific Manner Following Immunization with Cervarix and Gardasil in Adolescent and Young Adult Women in Vaccination Programs in Italy

Human papillomavirus (HPV) persistent infections are associated with cervical cancer and other HPV-related diseases and tumors. Thus, the characterization of long lasting immunity to currently available HPV vaccines is important. A total of 149 female subjects vaccinated with Cervarix or Gardasil pa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nicoli, Francesco, Mantelli, Barbara, Gallerani, Eleonora, Telatin, Valentina, Bonazzi, Irene, Marconi, Peggy, Gavioli, Riccardo, Gabrielli, Liliana, Lazzarotto, Tiziana, Barzon, Luisa, Palù, Giorgio, Caputo, Antonella
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7175219/ https://www.ncbi.nlm.nih.gov/pubmed/31947611 http://dx.doi.org/10.3390/vaccines8010026

Ejemplares similares

Differences in HPV-specific antibody Fc-effector functions following Gardasil® and Cervarix® vaccination
por: Roy, Vicky, et al.
Publicado: (2023)

Effects of the age of vaccination on the humoral responses to a human papillomavirus vaccine
por: Nicoli, Francesco, et al.
Publicado: (2022)

Cellular immunogenicity of human papillomavirus vaccines Cervarix and Gardasil in adults with HIV infection
por: Zurek Munk-Madsen, Maria, et al.
Publicado: (2017)

A Randomized, Observer-Blinded Immunogenicity Trial of Cervarix(®) and Gardasil(®) Human Papillomavirus Vaccines in 12-15 Year Old Girls
por: Draper, Eve, et al.
Publicado: (2013)

Efficacy of Human Papillomavirus L1 Protein Vaccines (Cervarix and Gardasil) in Reducing the Risk of Cervical Intraepithelial Neoplasia: A Meta-analysis
por: Haghshenas, Mohammad Reza, et al.
Publicado: (2017)

Impact of HPV vaccination with Gardasil® in Switzerland
por: Jacot-Guillarmod, Martine, et al.
Publicado: (2017)

Relationship between Humoral Immune Responses against HPV16, HPV18, HPV31 and HPV45 in 12-15 Year Old Girls Receiving Cervarix(®) or Gardasil(®) Vaccine
por: Godi, Anna, et al.
Publicado: (2015)

Update on Safety and Efficacy of HPV Vaccines: Focus on Gardasil
por: Soliman, Monica, et al.
Publicado: (2021)

The Tat Protein of HIV-1 Prevents the Loss of HSV-Specific Memory Adaptive Responses and Favors the Control of Viral Reactivation
por: Nicoli, Francesco, et al.
Publicado: (2020)

Cervarix(™): a vaccine for the prevention of HPV 16, 18-associated cervical cancer
por: Monie, Archana, et al.
Publicado: (2008)

Impaired Priming of SARS-CoV-2-Specific Naive CD8(+) T Cells in Older Subjects
por: Gallerani, Eleonora, et al.
Publicado: (2021)

Cross-neutralizing antibodies elicited by the Cervarix(®) human papillomavirus vaccine display a range of Alpha-9 inter-type specificities()
por: Bissett, Sara L., et al.
Publicado: (2014)

Use of a Novel Peptide Welding Technology Platform for the Development of B- and T-Cell Epitope-Based Vaccines
por: Nicoli, Francesco, et al.
Publicado: (2021)

Cervical intraepithelial neoplasia grade 3 in a patient following Gardasil vaccination
por: McLucas, Bruce, et al.
Publicado: (2019)

Projected impact of Cervarix™ vaccination on oncogenic human papillomavirus infection and cervical cancer in the United Kingdom
por: Van Effelterre, Thierry P, et al.
Publicado: (2015)

The HIV-1 Tat Protein Induces the Activation of CD8(+) T Cells and Affects In Vivo the Magnitude and Kinetics of Antiviral Responses
por: Nicoli, Francesco, et al.
Publicado: (2013)

A community intervention effectiveness study of single dose or two doses of bivalent HPV vaccine (CERVARIX®) in female school students in Thailand
por: Jiamsiri, Suchada, et al.
Publicado: (2022)

Guidelines of the Italian Society for Virology on HPV testing and vaccination for cervical cancer prevention
por: Barzon, Luisa, et al.
Publicado: (2008)

A novel vaccine for cervical cancer: quadrivalent human papillomavirus (types 6, 11, 16 and 18) recombinant vaccine (Gardasil(®))
por: Govan, Vandana A
Publicado: (2008)

Significantly Reduced Genoprevalence of Vaccine-Type HPV-16/18 Infections among Vaccinated Compared to Non-Vaccinated Young Women 5.5 Years after a Bivalent HPV-16/18 Vaccine (Cervarix®) Pilot Project in Uganda
por: Kumakech, Edward, et al.
Publicado: (2016)

An Attenuated Herpes Simplex Virus Type 1 (HSV1) Encoding the HIV-1 Tat Protein Protects Mice from a Deadly Mucosal HSV1 Challenge
por: Sicurella, Mariaconcetta, et al.
Publicado: (2014)

Incompletely Reported Important Methodological Details and Inaccurate Description of the Formulation That the Control Arms Received in a Gardasil Vaccine Trial
por: Bourgeois, Florence, et al.
Publicado: (2020)

Age-related decline of de novo T cell responsiveness as a cause of COVID-19 severity
por: Nicoli, Francesco, et al.
Publicado: (2020)

A novel trivalent HPV 16/18/58 vaccine with anti-HPV 16 and 18 neutralizing antibody responses comparable to those induced by the Gardasil quadrivalent vaccine in rhesus macaque model
por: Yin, Fei, et al.
Publicado: (2017)

Identification of new HIV-1 Gag-specific cytotoxic T lymphocyte responses in BALB/c mice
por: Cellini, Silvia, et al.
Publicado: (2008)

In Chronic Hepatitis C Infection, Myeloid-Derived Suppressor Cell Accumulation and T Cell Dysfunctions Revert Partially and Late After Successful Direct-Acting Antiviral Treatment
por: Telatin, Valentina, et al.
Publicado: (2019)

HPV Type 6 and 18 Coinfection in a Case of Adult-Onset Laryngeal Papillomatosis: Immunization with Gardasil
por: Fancello, Virginia, et al.
Publicado: (2015)

Vaccines for older adults; the low-hanging fruit of disease prevention
por: Wennekes, MD, et al.
Publicado: (2022)

Vaccine Development for Herpes Simplex Viruses: A Commentary of Special Issue Editors
por: Caputo, Antonella, et al.
Publicado: (2021)

Towards the eradication of HPV infection through universal specific vaccination
por: Crosignani, Piergiorgio, et al.
Publicado: (2013)

Incident HPV 51 Infection After Prophylactic Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine Gardasil/Silgard(®)
por: Halfon, Philippe, et al.
Publicado: (2010)

Reply to Bourgeois et al., “Incompletely Reported Important Methodological Details and Inaccurate Description of the Formulation That the Control Arms Received in a Gardasil Vaccine Trial”
por: Garland, Suzanne M., et al.
Publicado: (2020)

Long-Term Follow-up Observation of the Safety, Immunogenicity, and Effectiveness of Gardasil™ in Adult Women
por: Luna, Joaquin, et al.
Publicado: (2013)

Anti-Microbiota Vaccines Modulate the Tick Microbiome in a Taxon-Specific Manner
por: Mateos-Hernández, Lourdes, et al.
Publicado: (2021)

Characterization of a New CDC73 Missense Mutation that Impairs Parafibromin Expression and Nucleolar Localization
por: Masi, Giulia, et al.
Publicado: (2014)

Recombinant Envelope-Proteins with Mutations in the Conserved Fusion Loop Allow Specific Serological Diagnosis of Dengue-Infections
por: Rockstroh, Alexandra, et al.
Publicado: (2015)

High prevalence of cervical high-risk human papillomavirus infection mostly covered by Gardasil-9 prophylactic vaccine in adult women living in N’Djamena, Chad
por: Mboumba Bouassa, Ralph-Sydney, et al.
Publicado: (2019)

Focus group study on perceptions and information needs regarding vaccines targeting the older population: a cross-country comparison in four European countries
por: Wennekes, Manuela Dominique, et al.
Publicado: (2022)

Information networks of healthcare professionals in Europe on older adult vaccines: Network analysis
por: Wennekes, M D, et al.
Publicado: (2023)

Vaccination with TNF-α modulated DCs protects against CIA in an antigen-specific manner
por: van Duivenvoorde, LM, et al.
Publicado: (2004)

Cannot write session to /tmp/vufind_sessions/sess_56ro43p3qgrg060fe2ur1huo03